Hans-Dieter Orzechowski
Overview
Explore the profile of Hans-Dieter Orzechowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
577
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schultz O, Fiehn C, Kneitz C, Picker N, Kromer D, Zignani M, et al.
Z Rheumatol
. 2024 Apr;
84(1):39-47.
PMID: 38689038
Background: Real-world data for filgotinib, a Janus kinase (JAK)1 inhibitor, are limited in patients with rheumatoid arthritis (RA). Objectives: To explore real-world filgotinib use in patients with RA in Germany....
2.
Balsa A, Wassenberg S, Tanaka Y, Tournadre A, Orzechowski H, Rajendran V, et al.
Rheumatol Ther
. 2023 Sep;
10(6):1555-1574.
PMID: 37747626
Introduction: This post hoc analysis of the phase 3 rheumatoid arthritis (RA) filgotinib clinical trial program assessed the effect of filgotinib on body mass index (BMI) in patients with RA...
3.
Fiehn C, Zinke S, Haas J, Meise D, Theil J, Gurrath M, et al.
Z Rheumatol
. 2023 Feb;
82(9):739-753.
PMID: 36757417
Objective: To investigate treatment patterns in patients with rheumatoid arthritis (RA) in Germany who had previously received conventional synthetic (cs) or biologic (b) disease-modifying antirheumatic drugs (DMARDs). Methods: Patients with...
4.
Schmidt E, Sticherling M, Sardy M, Eming R, Goebeler M, Hertl M, et al.
J Dtsch Dermatol Ges
. 2020 May;
18(5):516-527.
PMID: 32413222
No abstract available.
5.
S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid: 2019 update
Schmidt E, Sticherling M, Sardy M, Eming R, Goebeler M, Hertl M, et al.
J Dtsch Dermatol Ges
. 2020 May;
18(5):516-526.
PMID: 32413212
No abstract available.
6.
Mevius A, Brandes A, Hardtstock F, Wilke T, Ratsch B, Orzechowski H, et al.
Digestion
. 2019 Oct;
102(2):216-226.
PMID: 31639807
Objectives: This study aimed to assess the real-world rates of treatment discontinuation and switching of biologic therapies in patients with inflammatory bowel disease (IBD). Methods: A retrospective claims data analysis...
7.
Brandes A, Groth A, Gottschalk F, Wilke T, Ratsch B, Orzechowski H, et al.
Z Gastroenterol
. 2019 Jul;
57(7):843-851.
PMID: 31288280
Objectives: This study aimed to describe biologic treatment of German inflammatory bowel disease (IBD) patients, including biologics' dosage, health care resource use, and treatment-associated cost. Methods: In this retrospective claims...
8.
Eming R, Sticherling M, Hofmann S, Hunzelmann N, Kern J, Kramer H, et al.
J Dtsch Dermatol Ges
. 2015 Jul;
13(8):833-44.
PMID: 26213827
No abstract available.
9.
Schmidt E, Goebeler M, Hertl M, Sardy M, Sitaru C, Eming R, et al.
J Dtsch Dermatol Ges
. 2015 Jun;
13(7):713-27.
PMID: 26110729
No abstract available.
10.
Douros A, Bronder E, Andersohn F, Klimpel A, Thomae M, Orzechowski H, et al.
Eur J Clin Pharmacol
. 2015 Jan;
71(3):387.
PMID: 25604511
No abstract available.